2020
LIMITED TESTING FOR CORONARY ARTERY DISEASE IN PATIENTS WITH NEW-ONSET HEART FAILURE: FINDINGS FROM GET WITH THE GUIDELINES - HEART FAILURE
O'Connor K, Brophy T, Fonarow G, Blankstein R, Swaminathan R, Xu H, Matsouaka R, Albert N, Velazquez E, Yancy C, Heidenreich P, Hernandez A, DeVore A. LIMITED TESTING FOR CORONARY ARTERY DISEASE IN PATIENTS WITH NEW-ONSET HEART FAILURE: FINDINGS FROM GET WITH THE GUIDELINES - HEART FAILURE. Journal Of The American College Of Cardiology 2020, 75: 866. DOI: 10.1016/s0735-1097(20)31493-5.Peer-Reviewed Original Research
2015
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)
Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O'Connor CM. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). The American Journal Of Cardiology 2015, 117: 404-411. PMID: 26704029, PMCID: PMC4718787, DOI: 10.1016/j.amjcard.2015.10.059.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedCause of DeathDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesFurosemideGlobal HealthHeart FailureHospitalizationHumansMaleMiddle AgedRetrospective StudiesSodium Potassium Chloride Symporter InhibitorsStroke VolumeSulfonamidesSurvival RateTorsemideTreatment OutcomeConceptsHeart failureChoice of diureticAcute heart failureDecompensated heart failureNatriuretic peptide levelsLow ejection fractionComparative effectiveness trialHF hospitalizationBlood pressureEjection fractionUnadjusted analysesAcute studyClinical effectivenessEffectiveness trialPeptide levelsPatientsFurosemideSimilar outcomesInverse probabilityPotential pharmacologicTorsemideDiureticsMortalityTrialsFailure